Brainstorm Cell Therapeutics Enacts Key Corporate Changes

Brainstorm Cell Therapeutics ( (BCLI) ) has issued an update.

Brainstorm Cell Therapeutics Inc. stockholders have given the green light to significant corporate updates in their recent virtual Annual Meeting. Key approvals include an increase of the shared pool of shares for two company incentive plans, the extension of these plans’ terms, and the authorization of a substantial rise in the number of authorized shares from 100 million to 250 million. Additionally, they granted the Board the flexibility to initiate a reverse stock split within a specified range, if deemed beneficial. These strategic decisions are poised to impact the company’s stock and governance, signaling potential growth and structural changes ahead.

Learn more about BCLI stock on TipRanks’ Stock Analysis page.